Biomarkers for precision therapy and prevention of type 2 diabetes
An Innovative Medicines Initiative Project for Precision Therapy and Prevention of Diabetes
RHAPSODY (“Risk Assessment and ProgreSsiOn of DIabetes”), a public private consortium funded by the Innovative Medicines Initiative (IMI) and EFPIA Companies with contributions from academic institutions, has announced the launch of a project focused on assessing the risk of progression of pre-diabetes to overt diabetes and of rapid deterioration of type 2 diabetes (T2D), a pandemic disease, which currently affects 285 million people worldwide. It is anticipated that this number will rise sharply to affect 439 million people worldwide by 2030, in particular spreading to the younger population.
Leading European experts from 20 academic institutions, 4 EFPIA pharmaceutical organizations and two SMEs officially launched the IMI project RHAPSODY. IMI is a unique Public Private Partnership between the pharmaceutical industry (represented by the European Federation of Pharmaceutical Industries and Associations / EFPIA) and the European Union. The EU contributes a total of EUR 2.5 billion over ten years, which is matched by dedicated resources provided by EFPIA member companies.
Three years into the project, the RHAPSODY team is eager to share its achievements with patient and healthcare communities in the Öresund region and welcomes all to a half-day symposium on March 10, 2020.
Date: 10 March 2020
Time: 14:00 – 17:00
Venue: Jubileumsaula, Scania University Hospital, Jan Waldenströms gata 1, 21428 Malmö, Sweden
By defining novel biomarkers for an improved taxonomy of type 2 diabetes and its progression, RHAPSODY intends to open up new roads towards diabetes prevention and treatment, and accelerate the development of personalised diabetes care.